Immunic Chairman Shows Confidence with Major Stock Options Grant Below $1

Rhea-AI Filing Summary

Immunic has filed a Form 4/A (amended insider trading report) for Executive Chairman and Director Duane Nash, correcting a previously filed Form 4 from June 9, 2025. The amendment addresses an administrative error in the reported number of stock options granted.

Key details of the transaction:

• Transaction Date: June 5, 2025
• Granted 570,000 stock options to purchase common stock
• Exercise price: $0.7729 per share
• Options expire on June 5, 2035
• Vesting schedule: Monthly increments over one year from grant date

This filing represents a significant equity compensation grant to a senior executive, with the options having a 10-year exercise period. The relatively low exercise price and substantial option quantity suggests a strong alignment of management interests with shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Nash Duane

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	570,000	$0.00	--

Holdings After Transaction: Stock Option — 570,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nash Duane

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/09/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.7729	06/05/2025		A		570,000		(1)	06/05/2035	Common Stock	570,000	$0.00	570,000	D

Explanation of Responses:

1. The option vests in monthly increments over a period of one year from the grant date.

Remarks:

This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.

	/s/ Duane Nash	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options were granted to Duane Nash at IMUX on June 5, 2025?

Duane Nash, Executive Chairman and Director of IMUX, was granted 570,000 stock options on June 5, 2025, with an exercise price of $0.7729 per share.

What is the vesting schedule for IMUX Executive Chairman's June 2025 stock options?

The stock options granted to Duane Nash vest in monthly increments over a one-year period from the grant date of June 5, 2025.

Why did IMUX file a Form 4/A amendment for Duane Nash's stock options?

IMUX filed the Form 4/A on June 28, 2025 to correct an administrative error in the original Form 4 filed on June 9, 2025, which had incorrectly reported the number of stock options granted to Duane Nash.

When do Duane Nash's IMUX stock options expire?

The stock options granted to Duane Nash expire on June 5, 2035, ten years from the grant date.

What positions does Duane Nash hold at IMUX according to the Form 4/A?

According to the Form 4/A filing, Duane Nash serves as both Executive Chairman and Director at Immunic, Inc. (IMUX).